Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06617312
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-24
Brief Title:
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-Reactivity
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Cytisinicline
Brief Summary:
This study will randomize 64 non-treatment seeking individuals who smoke cigarettes daily in a double-blind placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity
Detailed Description:
The objective of this study is to examine the effects of cytisinicline on neural substrates of cigarette cue-reactivity We will randomize 64 adults who smoke cigarettes daily N32 cytisinicline N32 placebo 50 female into a double-blind placebo-controlled laboratory study of cytisinicline Specifically participants will complete a 2- to 3-week outpatient protocol that includes taking cytisinicline 3 mg 3 times daily or matched placebo 0 mg 3 times daily and completing a brief daily diary assessment of cigarette use and craving Following 2- to 3-weeks of cytisinicline or placebo treatment participants will complete a cigarette cue-exposure task during fMRI Total study participation will be approximately 4 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None